Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

NASDAQ:KNSA   3:59:59 PM EDT
10.59
-0.57 (-5.11%)
Regulatory, Earnings Announcements

Kiniksa Announces Phase 3 Trial Of Mavrilimumab In Covid-19-Related ARDS Did Not Meet Primary Efficacy Endpoint

Published: 12/28/2021 12:11 GMT
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A (KNSA) - Kiniksa Announces Results From Phase 3 Trial of Mavrilimumab in Covid-19-related Ards.
Kiniksa Pharmaceuticals Ltd - Phase 3 Trial of Mavrilimumab in Covid-19-related Ards Did Not Meet Primary Efficacy Endpoint.
Kiniksa - Phase 3 Portion of Trial Did Not Meet Primary Efficacy Endpoint of Proportion of Patients Alive and Free of Mechanical Ventilation at Day 29.
Revenue is expected to be $17.17 Million
Adjusted EPS is expected to be -$0.42

Next Quarter Revenue Guidance is expected to be $18.7 Million
Next Quarter EPS Guidance is expected to be -$0.50

More details on our Analysts Page.